Broadfin Capital’s Allergan plc AGN Stock Holding History

Broadfin Capital’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-96,504	Closed	-$16.2M	–	56
2019 Q3	$16.2M	Sell	96,504 -18,300	-16%	-$2.98M	3%	8
2019 Q2	$19.2M	Buy	+114,804	New	+$15.9M	4.18%	8

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Broadfin Capital's AGN Position: Q4 2019 in Review

Broadfin Capital sold out of Allergan plc (AGN) in Q4 2019, closing a stake of 96,504 shares — an estimated $16.2M sold.

Broadfin Capital first reported a position in AGN in Q2 2019 and held it in 2 quarters. The position peaked at $19.2M in Q2 2019. 957 funds tracked by Wall St. Rank hold AGN as of Q4 2019.

Broadfin Capital reported no remaining Allergan plc position as of Q4 2019 after selling out during the quarter.
Broadfin Capital sold 96,504 Allergan plc shares in Q4 2019, an estimated $16.2M.
Broadfin Capital first reported a position in Allergan plc in Q2 2019 and held it in 2 quarters.
Broadfin Capital's Allergan plc position peaked at $19.2M in Q2 2019.
957 funds tracked by Wall St. Rank held Allergan plc as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.